TY - JOUR
T1 - Flying under the radar
T2 - The new wave of BCR-ABL inhibitors
AU - Quintás-Cardama, Alfonso
AU - Kantarjian, Hagop
AU - Cortes, Jorge
PY - 2007/10/1
Y1 - 2007/10/1
N2 - The introduction of the BCR-ABL kinase inhibitor imatinib mesylate (Gleevec; Novartis) revolutionized the treatment of chronic myeloid leukaemia (CML). However, most patients with CML receiving imatinib still harbour molecular residual disease and some develop resistance associated with ABL kinase domain mutations. The second-generation BCR-ABL inhibitors nilotinib (Tasigna; Novartis) and dasatinib (Sprycel; Bristol-Myers Squibb) have shown significant activity after imatinib failure in clinical trials, but still face similar obstacles to imatinib, including negligible activity against the frequent BCR-ABL T315I mutation and modest effects in advanced phases of CML. Various medicinal chemistry efforts, in part aided by structural studies of the ABL kinase-imatinib complex have resulted in the synthesis of a new generation of BCR-ABL inhibitors, some of which have shown encouraging preliminary activity in clinical trials, including against T315I mutants. Here, we discuss these emerging therapies, which have the potential to improve the outcome of patients with CML.
AB - The introduction of the BCR-ABL kinase inhibitor imatinib mesylate (Gleevec; Novartis) revolutionized the treatment of chronic myeloid leukaemia (CML). However, most patients with CML receiving imatinib still harbour molecular residual disease and some develop resistance associated with ABL kinase domain mutations. The second-generation BCR-ABL inhibitors nilotinib (Tasigna; Novartis) and dasatinib (Sprycel; Bristol-Myers Squibb) have shown significant activity after imatinib failure in clinical trials, but still face similar obstacles to imatinib, including negligible activity against the frequent BCR-ABL T315I mutation and modest effects in advanced phases of CML. Various medicinal chemistry efforts, in part aided by structural studies of the ABL kinase-imatinib complex have resulted in the synthesis of a new generation of BCR-ABL inhibitors, some of which have shown encouraging preliminary activity in clinical trials, including against T315I mutants. Here, we discuss these emerging therapies, which have the potential to improve the outcome of patients with CML.
UR - http://www.scopus.com/inward/record.url?scp=34848929062&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34848929062&partnerID=8YFLogxK
U2 - 10.1038/nrd2324
DO - 10.1038/nrd2324
M3 - Review article
C2 - 17853901
AN - SCOPUS:34848929062
SN - 1474-1776
VL - 6
SP - 834
EP - 848
JO - Nature Reviews Drug Discovery
JF - Nature Reviews Drug Discovery
IS - 10
ER -